卵巢癌III期试验:一线治疗格局的演变
该综述检索了clinicaltrials.gov上近期及正在进行的可能影响卵巢癌一线治疗的III期临床试验。共识别出12项在初始化疗中加入生物制剂和/或用于维持治疗的随机III期试验,以及7项采用腹腔热灌注化疗(HIPEC)的随机III期试验,其中10项试验正在进行中。
要点
- 12项一线卵巢癌随机III期试验探索PARP抑制剂、抗血管生成药物、免疫肿瘤药物及其联合方案。
- 上述12项试验中10项正在进行,1项因无效终止,1项近期已报告结果。
- 另识别出7项在初始卵巢癌治疗中采用HIPEC的随机III期试验。
核心结论
- 多项一线卵巢癌试验正在进行,研究PARP抑制剂、抗血管生成药物、免疫肿瘤药物及其联合方案和HIPEC。
- 许多试验将在未来几年内成熟,可能改变卵巢癌女性的一线治疗。
研究设计与样本
- 综述,检索clinicaltrials.gov上近期及正在进行的可能影响卵巢癌一线治疗的III期临床试验,总结其目标和可用数据。
主要发现
- 共识别出12项可能改变实践的随机III期一线卵巢癌试验,在初始化疗中加入生物制剂和/或用于维持治疗。
- 这些试验包括PARP抑制剂、抗血管生成药物、免疫肿瘤药物及其联合方案。
- 12项试验中10项正在进行,1项因无效终止,1项近期已报告。
- 所有试验均强调维持靶向治疗的使用。
- 另识别出7项在初始卵巢癌治疗中采用HIPEC的随机III期试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Ovarian cancer has a high mortality to case ratio. To improve the initial response to therapy, trials of biologic agents in combination with primary chemotherapy and as maintenance after completing chemotherapy are being conducted. Multiple trials are ongoing and this strategy has great promise. However, the changing landscape of primary treatment will make designing future trials in ovarian cancer difficult as there may not be a consensus on the optimal primary therapy. MATERIALS AND METHODS: We reviewed clinicaltrials.gov for recent and ongoing phase III clinical trials that are likely to impact primary therapy in ovarian cancer. We summarized the objectives and the available data from these trials. RESULTS: A total of 12 potentially practice-changing, randomized phase III trials in front line ovarian cancer were identified in which a biologic therapy was added to primary chemotherapy and/or was used in the maintenance setting. These trials included PARP inhibitors (PARPi), anti-angiogenic agents, immuno-oncology agents, and combinations of these agents. Of the 12 trials, 10 are ongoing, one was terminated for futility, and one has been recently reported. All of these trials emphasize the use of maintenance targeted therapy. In addition, 7 randomized phase III trials utilizing hyperthermic intraperitoneal chemotherapy (HIPEC) were identified in the setting of upfront ovarian cancer treatment. DISCUSSION: There are multiple ongoing trials in primary ovarian cancer. These trials investigate PARPi, anti-angiogenic agents, immuno-oncology agents, combinations of these agents, and HIPEC. Many of these trials will mature within the next several years and are likely to change the primary treatment of women with ovarian cancer.
引用
- Naumann RW, Coleman RL, Brown J, et al. Phase III trials in ovarian cancer: The evolving landscape of front line therapy. Gynecol Oncol. 2019. PMID: 30765149. doi:10.1016/j.ygyno.2019.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。